Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.65 |
| ▸ | TFEB | P19484 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112646 | 1.00 | HPGD (0.97) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL22110827 | 0.87 | HPGD (0.80) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL6788915 | 0.86 | HPGD (0.78) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL766007 | 0.86 | HPGD (0.73) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL16274575 | 0.82 | HPGD (0.67) | HPGDKDM4ENFE2L2ALDH1A1KMT2A | |
| SCHEMBL16274720 | 0.82 | HPGD (0.67) | HPGDKDM4ENFE2L2ALDH1A1KMT2A | |
| SCHEMBL28339657 | 0.81 | KDM4E (0.85) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL28339655 | 0.81 | KDM4E (0.85) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL766028 | 0.81 | HPGD (0.65) | HPGDKDM4EMAPTNPC1RAB9A | |
| SCHEMBL791546 | 0.81 | HPGD (0.65) | HPGDKDM4EMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | claimed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | claimed |
| EP-2725011-B1 | NOVEL BASE GENERATOR AND ADHESION ENHANCER | TOKYO OHKA KOGYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-20160170302-A1 | NOVEL COMPOUND | TOKYO OHKA KOGYO CO LTD (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160170302-A1 | NOVEL COMPOUND | TOKYO OHKA KOGYO CO LTD (JP) | 2016-06-16 | — | — | US | disclosed |
| US-9244346-B2 | Negative-type photosensitive resin composition, pattern forming method, cured film, insulating film, color filter, and display device | TOKYO OHKA KOGYO CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-9244346-B2 | Negative-type photosensitive resin composition, pattern forming method, cured film, insulating film, color filter, and display device | TOKYO OHKA KOGYO CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20140231729-A1 | NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERN FORMING METHOD, CURED FILM, INSULATING FILM, COLOR FILTER, AND DISPLAY DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140231729-A1 | NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERN FORMING METHOD, CURED FILM, INSULATING FILM, COLOR FILTER, AND DISPLAY DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| EP-2725011-A1 | NOVEL COMPOUND | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | disclosed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-7122561-B2 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-20040061142-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2004-04-01 | — | — | US | disclosed |
| US-6680391-B2 | PIPERINE AND ANALOGUES OR DERIVATIVES FOR THE TREATMENT OF SKIN CONDITIONS TREATABLE BY STIMULATING MALENOCYTE PROLIFERATION, SUCH AS VITILGO, AND ALSO FOR SKIN CANCER | BTG INTERNATIONAL LIMITED (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20020168369-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2002-11-14 | — | — | US | disclosed |
| US-6346539-B1 | ADMINISTERING PIPERINE DERIVATIVE TO TREAT VITILIGO AND MELANOMA; STIMULATING MELANOCYTE PROLIFERATION; ANTICARCINOGENIC AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | PRPH, BDNF, GAP43 | HPGD 357/4885KDM4E 2120/4885MAPT 296/4885 |
| US-20020168369-A1 | Treatment of skin conditions | TYR, MC1R, MITF | HPGD 310/4885KDM4E 643/4885MAPT 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.